Barclays
CTXR icon

Barclays’s Citius Pharmaceuticals CTXR Stock Holding History

Barclays’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-29
Closed -$43 – 5314
2025
Q1 		$43 Buy
+29
New +$69 ﹤0.01% 5150
2024
Q4 		– Hold
0
– -$1 – 5311
2024
Q3 		– Sell
-1,513
Closed -$25.5K – 5261
2024
Q2 		$22.1K Sell
1,513
-2,266
-60% -$40.6K ﹤0.01% 4423
2024
Q1 		$84.8K Sell
3,779
-2,974
-44% -$54.3K ﹤0.01% 4491
2023
Q4 		$128K Buy
6,753
+5,882
+675% +$112K ﹤0.01% 4573
2023
Q3 		$14.9K Sell
871
-109
-11% -$2.59K ﹤0.01% 4234
2023
Q2 		$29.4K Buy
+980
New +$32.3K ﹤0.01% 4044
2022
Q4 		– Sell
-135
Closed -$4K – 5283
2022
Q3 		$4K Sell
135
-129
-49% -$3.54K ﹤0.01% 4530
2022
Q2 		$6K Sell
264
-540
-67% -$14.8K ﹤0.01% 4744
2022
Q1 		$36K Sell
804
-4,709
-85% -$186K ﹤0.01% 4237
2021
Q4 		$212K Buy
5,513
+3,657
+197% +$166K ﹤0.01% 3543
2021
Q3 		$94K Sell
1,856
-247
-12% -$12.4K ﹤0.01% 3923
2021
Q2 		$183K Buy
2,103
+1,729
+462% +$104K ﹤0.01% 3595
2021
Q1 		$17K Buy
+374
New +$14.9K ﹤0.01% 4393
2020
Q1 		– Hold
0
– – – 6185
2019
Q4 		– Hold
0
– – – 6413

Other funds holding CTXR

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

Barclays's CTXR Position: Q2 2025 in Review

Barclays sold out of Citius Pharmaceuticals (CTXR) in Q2 2025, closing a stake of 29 shares — an estimated $43 sold.

Barclays first reported a position in CTXR in Q1 2021 and held it in 13 quarters. The position peaked at $212K in Q4 2021. 31 funds tracked by Wall St. Rank hold CTXR as of Q2 2025.

  • Barclays reported no remaining Citius Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Barclays sold 29 Citius Pharmaceuticals shares in Q2 2025, an estimated $43.
  • Barclays first reported a position in Citius Pharmaceuticals in Q1 2021 and held it in 13 quarters.
  • Barclays's Citius Pharmaceuticals position peaked at $212K in Q4 2021.
  • 31 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.